The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Sub-anesthetic concentrations of (R, S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors
Open accessAbstract
The effect of the (R,S)-ketamine metabolites (R,S)-norketamine, (R,S)-dehydronorketamine, (2S,6S)-hydroxynorketamine and (2R,6R)-hydroxynorketamine on the activity of α7 and α3β4 neuronal nicotinic acetylcholine receptors was investigated using patch-clamp techniques. The data indicated that (R,S)-dehydronorketamine inhibited acetylcholine-evoked currents in α7-nicotinic acetylcholine receptor, IC(50) = 55 ± 6 nM, and that (2S,6S)-hydroxynorketamine, (2R,6R)-hydroxynorketamine and (R,S)-norketamine also inhibited α7-nicotinic acetylcholine receptor function at concentrations ≤ 1 μM, while (R,S)-ketamine was inactive at these concentrations. The inhibitory effect of (R,S)-dehydronorketamine was voltage-independent and the compound did not competitively displace selective α7-nicotinic acetylcholine receptor ligands [(125)I]-α-bungarotoxin and [(3)H]-epibatidine indicating that (R,S)-dehydronorketamine is a negative allosteric modulator of the α7-nicotinic acetylcholine receptor. (R,S)-Ketamine and (R,S)-norketamine inhibited (S)-nicotine-induced whole-cell currents in cells expressing α3β4-nicotinic acetylcholine receptor, IC(50) 3.1 and 9.1 μM, respectively, while (R,S)-dehydronorketamine, (2S,6S)-hydroxynorketamine and (2R,6R)-hydroxynorketamine were weak inhibitors, IC(50) >100 μM. The binding affinities of (R,S)-dehydronorketamine, (2S,6S)-hydroxynorketamine and (2R,6R)-hydroxynorketamine at the NMDA receptor were also determined using rat brain membranes and the selective NMDA receptor antagonist [(3)H]-MK-801. The calculated K(i) values were 38.95 μM for (S)-dehydronorketamine, 21.19 μM for (2S,6S)-hydroxynorketamine and>100 μM for (2R,6R)-hydroxynorketamine. The results suggest that the inhibitory activity of ketamine metabolites at the α7-nicotinic acetylcholine receptor may contribute to the clinical effect of the drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“(2R,6R)-HNK has a binding affinity (Ki) and IC50 greater than 100 μM with 24% inhibition at 100 μM, and fails to impact NMDA-evoked currents in CA1 interneurons (Moaddel et al., 2013; Morris et al., 2017; Zanos et al., 2016).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Moaddel et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“its inability to displace MK-801 binding to NMDARs (10 μM).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Moaddel et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Important for the mechanism of action of (2R,6R)-HNK as an antidepressant (and thus ketamine’s action) is the fact that at relevant concentrations (i.e., 10 mg/kg or brain Cmax = ~10 μmol/kg in mice), (2R,6R)-HNK does not appear to inhibit the NMDAR.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [112]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“(S)-ketamine has ~4-fold greater affinity/potency at inhibiting the NMDAR compared to its (R)-ketamine enantiomer 13, 111–115.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [112]
In the citing paper
“[3H]-MK-801 binding displacement studies showed that the affinity of (2R,6R)-HNK to displace MK-801 from the NMDAR is >100 μM, and that of (2S,6S)-HNK is 7–20 μM 111, 112.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.
Wong, E. H. F., Kemp, J. A., Priestley, T., Knight, A. R., Woodruff, G. N., & Iversen, L. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.18.7104 · Cited by 1,820
X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel
Nury, H., Van Renterghem, C., Weng, Y., Tran, A., Baaden, M., Dufresne, V., Changeux, J.-P., Sonner, J. M., Delarue, M., & Corringer, P.-J. (2011) · Nature · doi:10.1038/nature09647 · Cited by 412
Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis
Mineur, Y. S., & Picciotto, M. R. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.004 · Cited by 285
Zarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
Self-citationAnalysis of Mecamylamine Stereoisomers on Human Nicotinic Receptor Subtypes
Papke, R. L., Sanberg, P. R., & Shytle, R. D. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29581-1 · Cited by 271
Ebert, B., Mikkelsen, S. S., Thorkildsen, C., & Borgbjerg, F. M. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01116-3 · Cited by 270
Xiao, Y., Meyer, E. L., Thompson, J. M., Surin, A. M., Wroblewski, J. T., & Kellar, K. J. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.2.322 · Cited by 247
Self-citationPhilip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1932-6 · Cited by 191
Ketamine: new uses for an old drug?
Hirota, K., & Lambert, D. G. (2011) · British Journal of Anaesthesia · doi:10.1093/bja/aer221 · Cited by 160
Yamakura, T., Chavez-Noriega, L. E., & Harris, R. A. (2000) · Anesthesiology · doi:10.1097/00000542-200004000-00033 · Cited by 141
Cited by
Sorted by citations
Items 101–176 of 176
Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions
Onisiforou, A., Georgiou, P., & Zanos, P. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173531 · Cited by 12
Brown, K. A., Ajibola, M. I., & Gould, T. D. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02085-4 · Cited by 15
Faccio, A. T., Rupérez, F. J., Singh, N., Angulo, S., Tavares, M. F. M., Bernier, M., Barbas, C., & Wainer, I. W. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.03.008 · Cited by 13
Self-citationDistinct cognitive and discriminative stimulus effects of ketamine enantiomers in rats
Popik, P., Khoo, S. Y., Kuziak, A., Gołębiowska, J., Potasiewicz, A., Hogendorf, A. S., Popik, O., Matłoka, M., Moszczyński-Pętkowski, R., Nikiforuk, A., et al. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173011 · Cited by 14
Sandbaumhüter, F. A., Theurillat, R., & Thormann, W. (2017) · Electrophoresis · doi:10.1002/elps.201700016 · Cited by 17
Assessment of the rapid and sustained antidepressant-like effects of dextromethorphan in mice
Saavedra, J. S., Garrett, P. I., Honeycutt, S. C., Peterson, A. M., White, J., & Hillhouse, T. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173003 · Cited by 14
Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression
Price, M. Z., & Price, R. L. (2024) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2024.100104 · Cited by 15
Pharmacology of ketamine and esketamine as rapid-acting antidepressants
Pavlidi, P., Megalokonomou, A., Sofron, A., Kokras, N., & Dalla, C. (2021) · Psychiatriki · doi:10.22365/jpsych.2021.050 · Cited by 12
Is there a risk of esketamine misuse in clinical practice?
Roncero, C., Torres, M. M., Szerman, N., Torrens, M., Vega, P., Andrés-Olivera, P., & Alvarez, E. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241310685 · Cited by 16
Emnett, C. M., Li, H., Jiang, X., Benz, A. M., Boggiano, J., Conyers, S. B., Wozniak, D. F., Zorumski, C. F., Reichert, D. E. C., & Mennerick, S. J. (2016) · Scientific Reports · doi:10.1038/srep38808 · Cited by 13
Duarte, Y., Rojas, M., Canan, J., Pérez, E. G., González-Nilo, F. D., & García‐Colunga, J. (2021) · Molecules · doi:10.3390/molecules26040998 · Cited by 13
Jiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 11
Ketamine Metabolomics in the Treatment of Major Depression
van Velzen, M., & Dahan, A. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000286 · Cited by 11
The effects of (2R,6R)-hydroxynorketamine on oxycodone withdrawal and reinstatement
Drinkuth, C. R., Lehane, M. J., & Sartor, G. C. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.110987 · Cited by 10
Sajid, S., Galfalvy, H., Keilp, J. G., Burke, A. K., Mann, J. J., & Grunebaum, M. F. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae017 · Cited by 12
Enantioselective inhibition of d‐serine transport by (S)‐ketamine
Singh, N. S., Bernier, M., Camandola, S., Khadeer, M. A., Moaddel, R., Mattson, M. P., & Wainer, I. W. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13239 · Cited by 11
Self-citationAntidepressants enter cells, organelles, and membranes
Blumenfeld, Z., Bera, K., Ċastrén, E., & Lester, H. A. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01725-x · Cited by 10
Guhathakurta, D., Petrušková, A., Akdaş, E. Y., Perelló‐Amorós, B., Frischknecht, R., Anni, D., Weiss, E., Walter, M., & Fejtová, A. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02744-y · Cited by 10
Lauretti, G. R. (2014) · Journal of Physical Chemistry & Biophysics · doi:10.4172/2161-0398.1000154 · Cited by 10
Colla, M., Scheerer, H., Weidt, S., Seifritz, E., & Kronenberg, G. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.759466 · Cited by 10
Wang, H., Duan, C., Zhang, J., Qu, S., Sun, Y., Zhou, L., Yang, L., Lan, C., Mi, W., & Chen, P. (2022) · Trials · doi:10.1186/s13063-022-06534-z · Cited by 9
The role of nicotinic receptors in alcohol consumption
Kamens, H. M., Flarend, G., & Horton, W. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106705 · Cited by 8
Sandbaumhüter, F. A., Theurillat, R., Bettschart‐Wolfensberger, R., & Thormann, W. (2017) · Electrophoresis · doi:10.1002/elps.201700017 · Cited by 8
Rodd, Z. A., Hauser, S. R., Swartzwelder, H. S., Waeiss, R. A., Lahiri, D. K., & Bell, R. L. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05557-1 · Cited by 8
Reyes-Parada, M. I., & Iturriaga‐Vásquez, P. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1227317 · Cited by 8
Pitsikas, N. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112778 · Cited by 8
Cortical Mechanisms Contributing to Ketamine-Induced Dissociation
Bera, K., Looger, L. L., Proekt, A., & Cichon, J. (2025) · The Neuroscientist · doi:10.1177/10738584251403946 · Cited by 9
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen, W., Zhao, W., Xia, X., Duan, X., Zhang, L., Lin, D., Qi, Z., Wang, S., Gao, M., Liu, C., et al. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173773 · Cited by 9
Costa, A. L. L., Silva, R. C., Coelho-Cordeiro, P. H., da Silveira, F. S., Barros, M., Caixeta, F. V., & Maior, R. S. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.641776 · Cited by 7
Glutamatergic Agents for the Treatment of Cocaine Use Disorder
Hadizadeh, H., Flores, J. M., Mayerson, T. F., Worhunsky, P. D., Potenza, M. N., & Angarita, G. A. (2022) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-022-00252-1 · Cited by 7
Yost, J. G., Browne, C. A., & Lucki, I. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109276 · Cited by 7
Liu, A.-R., Lin, Z., Wei, M., Tang, Y., Zhang, H., Peng, X.-G., Li, Y., Zheng, Y., Tan, Z., Zhou, L., et al. (2023) · The Journal of Headache and Pain · doi:10.1186/s10194-023-01667-1 · Cited by 7
The Basic and Clinical Pharmacology of Ketamine
Fourcade, E. W., & Lapidus, K. A. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_2 · Cited by 7
A synopsis of multitarget therapeutic effects of anesthetics on depression
Wu, G., & Xu, H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176032 · Cited by 6
Effects of adolescent substance use disorders on central cholinergic function
Hauser, S. R., Rodd, Z. A., Deehan, G. A., Liang, T., Rahman, S., & Bell, R. L. (2021) · International review of neurobiology · doi:10.1016/bs.irn.2021.07.008 · Cited by 7
Targeting Affective Mood Disorders With Ketamine to Prevent Chronic Postsurgical Pain
Willis, D. E., & Goldstein, P. A. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.872696 · Cited by 6
Wehrman, J., Casey, C., Tanabe, S., Mohanta, S., Filbey, W., Weber, L. A. E., Banks, M. I., Pearce, R. A., Saalmann, Y. B., & Sanders, R. D. (2023) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.06.044 · Cited by 7
Ketamine Inhibition of the Pentameric Ligand-Gated Ion Channel GLIC
Ion, B. F., Wells, M. M., Chen, Q., Xu, Y., & Tang, P. S. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.06.041 · Cited by 6
Zannikos, P., Solanki, B., Meulder, M. D., Badorrek, P., Hohlfeld, J. M., & Singh, J. B. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01273-z · Cited by 5
Kovacova, V., Macejova, A., Tonhajzerová, I., Višňovcová, Z., Ferencová, N., Mlyncekova, Z., Kukucka, T., Farský, I., Nosáľ, S., & Ondrejka, I. (2024) · Pharmaceuticals · doi:10.3390/ph17030358 · Cited by 6
The rapid‐onset antidepressant effect of ketamine: More surprises?
Raffa, R. B., Pergolizzi, J. V., & Taylor, R. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12656 · Cited by 5
Insights for the Next Generation of Ketamine for the Treatment of Depressive Disorder
Martins, A. C. F., Badenoch, B., & Gomes, R. D. S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02467 · Cited by 4
Process for (S)-Ketamine and (S)-Norketamine via Resolution Combined with Racemization
Gao, S., Gao, X., Wu, Z., Li, H., Yang, Z., & Zhang, F. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c01090 · Cited by 4
On the Eve of Upgrading Antidepressants: (R)-Ketamine and Its Metabolites
Yuan, K., Han, Y., Hashimoto, K., & Lü, L. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0082-1 · Cited by 4
Zandona, A. (2020) · Periodicum Biologorum · doi:10.18054/pb.v121-122i3-4.10547 · Cited by 5
Effects of the antidepressant mirtazapine and zinc on nicotinic acetylcholine receptors
Hernández-Abrego, A., Vázquez-Gómez, E., & García‐Colunga, J. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.12.016 · Cited by 4
Ketamine blocks morphine-induced conditioned place preference and anxiety-like behaviors in micePreprint
McKendrick, G., Garrett, H., Jones, H. E., McDevitt, D. S., Sharma, S., Silberman, Y., & Graziane, N. M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.22.915728 · Cited by 4
Barilone, N., Vangelatou, M., Marouf, F. Z., de la Bâtie, G. D., Li, Q., Lafaye, P. J., Aymé, G., Corringer, P., & Prevost, M. S. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2514734123 · Cited by 3
Pharmacokinetics and pharmacodynamics of orally administered S-ketamine in healthy participants
van Mechelen, J., Wieles, T., Borghans, L. G. J. M., Otto, M. E., Juachon, M. J., Gillespie, A. L., van Noorden, M. S., Harmer, C. J., van Hemert, A. M., van Gerven, J. M. A., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261456187 · Cited by 3
The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression
Molero, P., Aubá, E., Unceta, M. D. M., & Pedreño, F. O. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_11 · Cited by 2
(2R,6R)-Hydroxynorketamine, A Metabolite of Ketamine: The Antidepressant Actions and the Mechanisms
Fukumoto, K., & Duman, R. S. (2021) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-79790-4_2 · Cited by 1
Esketamine-Induced Dissociation: A Case Report
Scarcella, J., MacDaniels, J. S., Coffin, L., & Schwartz, T. L. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2424283 · Cited by 1
Deyama, S., Mishiro, K., Kunishima, M., & Kaneda, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178301 · Cited by 1
Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science
van Hoogdalem, M. W., Fu, D., Drevets, W. C., & Zannikos, P. (2026) · Clinical and Translational Science · doi:10.1111/cts.70527 · Cited by 2
Wainer, I. W. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3736-6 · Cited by 1
Self-citationGonzález-Pinto, A. M. (2020) · Psiquiatría Biológica · doi:10.1016/j.psiq.2020.01.001 · Cited by 1
Diverse pharmacological properties of ketamine
Laher, I., Zhang, X., Leung, P. C., & Liang, W. (2015) · CRC Press eBooks · doi:10.1201/b18230-4 · Cited by 1
Current and Future Trends in Drug Discovery and Development Related to Nicotinic Receptors
Arnerić, S. P., & Sher, E. (2014) · The Receptors · doi:10.1007/978-1-4939-1167-7_21 · Cited by 1
Ketamine — a unique adjuvant drug in pain treatment
Rupniewska-Ładyko, A. (2020) · Palliative Medicine in Practice · doi:10.5603/pmpi.2020.0023 · Cited by 1
Ketamine and Other Glutamate Receptor Antagonists As Fast-Actin
Chen, M., Su, T., & Tsai, S. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_19 · Cited by 1
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_420 · Cited by 1
Soll, L. G. (2013) · eScholarship@UMassChan · doi:10.13028/m2ng64
Diverse pharmacological properties of ketamine
Laher, X. Z. I. (2015) · CRC Press eBooks · doi:10.1201/b18230-7
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_420-1 · Cited by 1
Analgesia with Ketamine and Its Metabolites: Mechanisms and Effects
Boucherie, D. E., Schrantee, A., Hollmann, M. W., & Brinkman, D. J. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_10
Ketamine’s Multifaceted Neuropharmacological and Neurobiological Actions
Kohtala, S., & Annala, I. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_2
Lehane, M. J., & Sartor, G. C. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06924-6
Ketamine and its metabolites—Mechanism of action
Kneebusch, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00010-2
Liu, A.-R., Lin, Z., Wei, M., Tang, Y., Zhang, H., 彭向阁, Li, Y., Zheng, Y.-F., Tan, Z., Zhou, L.-J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26628997
Comparative EEG analysis of the effects of ketamine enantiomers and metabolites in rhesus macaques
Iwamura, Y., Nishigori, K., Yamaguchi, M., Ogi, Y., Kobayashi, A., Iwasaki, T., Nagata, H., & Ikeda, K. (2026) · Journal of Neurophysiology · doi:10.1152/jn.00203.2025 · Cited by 1
Martin, E. (2017) · theses.fr (ABES) · doi:10.70675/3f77e643zf119z465fzbc28z20877ecebf8e
Prise en charge médicamenteuse des patients souffrant de douleur chronique réfractaire
Corriger, A. (2019) · theses.fr (ABES) · doi:10.70675/668e4777zf8d0z4bdcz9780z0f91fedfe2b6
Impact of open channel blockers on the surface dynamics and organization of NMDA receptors
Fernandes, A. (2020) · theses.fr (ABES) · doi:10.70675/d12c14b2z7a80z4668z9c48z8e2c0e41c009 · Cited by 1
Mansari, M. E., Okamoto, N., & Blier, P. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyag020
The Comparative Sensitivity to Ketamine-Induced Neuronal Death in Juvenile and Adult Rats
Sarkar, S., da Costa, G. G., Woodling, K. A., Mathew, S., Elayan, I., & Talpos, J. C. (2026) · International Journal of Toxicology · doi:10.1177/10915818261455819
BindingDB Entry 50011888: Repurposing of Drugs-The Ketamine Story.
BindingDB (2022) · UC San Diego · doi:10.7270/q2t15797
Metadata
- Authors
- Moaddel, R., Abdrakhmanova, G., Kozak, J., Jozwiak, K., Toll, L., Jimenez, L., Rosenberg, A., Tran, T., Xiao, Y., Zarate, C. A., & Wainer, I. W.
- Affiliations
- National Institutes of Health (US)
- Virginia Commonwealth University (US)
- Medical University of Lublin (PL)
- Torrey Pines Institute For Molecular Studies (US)
- SRI International (US)
- Georgetown University (US)
- Corresponding author
- Wainer, Irving W.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 698
- Issue
- 1-3
- Pages
- 228-234
- ISSN
- 0014-2999 (ISSN-L)
- PMC
- PMC3534778
- OpenAlex
- W2068032560
- Cited by
- 176
- References
- 22
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 11 · 2023: 14 · 2022: 14 · 2021: 15 · 2020: 23 · 2019: 11 · 2018: 15 · 2017: 16 · 2016: 15 · 2015: 14 · 2014: 9 · 2013: 4
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Journal of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Intramural Research Programs of the National Institute of Aging (IWW)
- National Institute of Mental Health (CAZ)
- Brain & Behavior Research Foundation Bipolar Disorders Award (CAZ), NIA (N01AG-3–1009 (GA,LT,LJ))
- Foundation for Polish Science (FOCUS and TEAM Programmes) (KJ).
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Keywords
- ketamine metabolites, norketamine, dehydronorketamine, hydroxynorketamine, alpha7 nicotinic acetylcholine receptor, α3β4 nicotinic acetylcholine receptor, negative allosteric modulation, NMDA receptor binding, nicotinic antagonists
- MeSH terms
- Acetylcholine, Anesthetics, Animals, Cell Line, Dose-Response Relationship, Drug, Ketamine, Receptors, Nicotinic, Receptors, N-Methyl-D-Aspartate, Nicotinic Agonists, Rats, Electrophysiological Phenomena, alpha7 Nicotinic Acetylcholine Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
